Literature DB >> 14304354

TREATMENT OF BENIGN PROSTATIC HYPERTROPHY WITH HYDROXYPROGESTERONE CAPROATE: EFFECT ON CLINICAL SYMPTOMS, MORPHOLOGY, AND ENDOCRINE FUNCTION.

J GELLER, R BORA, T ROBERTS, H NEWMAN, A LIN, R SILVA.   

Abstract

Entities:  

Keywords:  BIOPSY; DRUG THERAPY; GONADOTROPINS, PITUITARY; HYDROXYPROGESTERONE; LH; PATHOLOGY; PROSTATIC HYPERTROPHY; URINE

Mesh：

Substances：

Year:  1965        PMID： 14304354     DOI： 10.1001/jama.1965.03090020035009

Source DB:  PubMed          Journal:  JAMA        ISSN： 0098-7484            Impact factor:   56.272


× No keyword cloud information.
  8 in total

Review 1.  The relationship between consultation length, process and outcomes in general practice: a systematic review.

Authors:  Andrew Wilson; Susan Childs
Journal:  Br J Gen Pract       Date:  2002-12       Impact factor: 5.386

2.  Effects of cimetidine, progesterone, cannitracin and tolazoline on the weight and DNA content of the testosterone-induced hyperplastic prostate of the rat.

Authors:  W Chen; X M Zhou; D Y Chen; J S Kang
Journal:  Urol Res       Date:  1988

3.  [Experimental studies with cyclic imides in dimethylbenzanthracene tumors of Sprague-Dawley rats].

Authors:  H Mückter; E Frankus; E Moré; W E Kollmer; M Staemmler
Journal:  Z Krebsforsch       Date:  1967

4.  [Diagnosis and conservative treatment of the prostatic adenoma].

Authors:  W Brosig
Journal:  Langenbecks Arch Chir       Date:  1972

Review 5.  A risk-benefit assessment of treatment with finasteride in benign prostatic hyperplasia.

Authors:  P Ekman
Journal:  Drug Saf       Date:  1998-03       Impact factor: 5.606

6.  Dihydrotestosterone in prostatic hypertrophy. I. The formation and content of dihydrotestosterone in the hypertrophic prostate of man.

Authors:  P K Siiteri; J D Wilson
Journal:  J Clin Invest       Date:  1970-09       Impact factor: 14.808

7.  Androgen receptor content of the normal and hyperplastic canine prostate.

Authors:  S A Shain; R W Boesel
Journal:  J Clin Invest       Date:  1978-03       Impact factor: 14.808

8.  Gestagens in the management of prostatic carcinoma.

Authors:  Z Szendröi
Journal:  Int Urol Nephrol       Date:  1984       Impact factor: 2.370
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.